RxSight (RXST)

• Market cap: $1.22B
• 1 day: -2.53%
• 5 days: -6.95%
• 1 month: -20.11%
• 3 months: -39.26%
• 6 months: -35.64%
• Year to date: -12.04%
• 1 year: -33.28%
• 5 years: 89.94%
• 10 years: 89.94%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 374

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,355% more call options, than puts

Call options by funds: $23.1M | Put options by funds: $1.59M

34% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 65

6.3% less ownership

Funds ownership: 92.3% [Q2] → 86.0% (-6.3%) [Q3]

7% less funds holding

Funds holding: 227 [Q2] → 212 (-15) [Q3]

22% less capital invested

Capital invested by funds: $2.16B [Q2] → $1.69B (-$478M) [Q3]

25% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 44

71% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 2 (-5) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 15% upside
• Avg. target: $53 74% upside
• High target: $72 137% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target	32% upside $40	Equal-Weight Maintained	13 Jan 2025
Stifel Thomas Stephan 29% 1-year accuracy 5 / 17 met price target	15% upside $35	Hold Maintained	13 Jan 2025
Needham David Saxon 34% 1-year accuracy 21 / 62 met price target	117% upside $66	Buy Reiterated	13 Jan 2025
UBS Danielle Antalffy 58% 1-year accuracy 7 / 12 met price target	71% upside $52	Buy Initiated	6 Dec 2024
Jefferies Young Li 0% 1-year accuracy 0 / 2 met price target	137% upside $72	Buy Initiated	29 Oct 2024